Lead Program RORĪ³t - One of the hottest immunology targets

Lead Pharma has identified novel inhibitors of RORyt (retinoic acid receptor-related orphan receptor gamma), which is currently one of the hottest immunology targets and a member of the classic drug target family of nuclear receptors. It regulates the production of key pro-inflammatory proteins, including interleukin (IL)-17A, IL-17F and the receptor for IL-23. The IL-17 pathway has a critical role in chronic autoimmune-related inflammation, and a modulation of RORyt by small molecules bears great potential for the treatment of auto-immune diseases. However, with large and lipophilic ligand-binding domains RORyt is very difficult to address.


The program was partnered with Sanofi in early 2015.